April 9, 2026 — Core compound patents for semaglutide, the molecule behind Novo Nordisk's blockbuster Ozempic and Wegovy brands, expired in India and China on March 20, 2026. This watershed moment has triggered a rush among generic drug manufacturers to enter the multi-billion-dollar GLP-1 receptor agonist market.
The global GLP-1 receptor agonist market, currently valued at approximately $50 billion annually, is projected to reach $130 billion by 2030. Semaglutide alone accounts for over $20 billion in annual sales across its diabetes (Ozempic), obesity (Wegovy), and oral (Rybelsus) formulations.
At least 12 major Indian pharmaceutical companies have announced plans to launch semaglutide generics, including Sun Pharma, Dr. Reddy's, Zydus Lifesciences, and Glenmark. Natco Pharma has announced plans to offer generic semaglutide at approximately $14 per month — representing an 80-90% discount versus current branded pricing of $108-173 per month in India.
Semaglutide is a complex 31-amino-acid peptide with multiple non-standard modifications including a C18 fatty diacid side chain. This complexity creates significant barriers to entry but also substantial opportunities for qualified peptide API manufacturers:
Custom peptide synthesis: Demand for GMP-grade semaglutide API will surge
Specialty intermediates: Protected amino acids and fatty acid linkers
Lyophilization services: Final drug product manufacturing capabilities
While patent protection remains intact in the United States (through 2032-2033) and Europe (through 2031), the opening of Asian markets creates immediate commercial opportunities for API suppliers positioned to support generic manufacturing scale-up.
